相关实验视频
Updated: Jul 22, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
维持治疗儿童急性淋巴细胞白血病的药理动力学模型
Anna Gebhard1, Patrick Lilienthal2, Markus Metzler3
1MathOpt group, Institute of Mathematical Optimization, Faculty of Mathematics, Otto von Guericke University Magdeburg, Magdeburg, Germany. anna.gebhard@ovgu.de.
这项研究开发了儿童急性淋巴细胞白血病 (ALL) 维持药物6-mercaptopurine (6MP) 和甲状腺素 (MTX) 的药理动力学模型. 这些模型预测了个体中性粒细胞的数量,帮助个性化ALL治疗策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 儿科瘤学 儿科瘤学
- 数学建模的数学建模
背景情况:
- 目前的儿童急性淋巴细胞白血病 (ALL) 治疗结合了密集化疗与6 - 默卡波图 (6MP) 和甲状腺素 (MTX) 维持疗法.
- 虽然生存率接近90%,但药物反应的显著患者间变化阻碍了个性化治疗.
- 了解剂量反应关系对于优化ALL管理至关重要.
研究的目的:
- 开发儿童ALL中的6MP和MTX的药理动力学 (PK) 和药理动力学-药理动力学 (PKPD) 模型.
- 预测个体绝对中性粒细胞计数 (ANC) 水平,用于个性化治疗策略.
- 评估将红细胞代谢物测量整合到PKPD模型中的影响.
主要方法:
- 使用了详细的数据集,包括红细胞瓜氨酸核酸和MTX水平,以及ANC.
- 为6MP和MTX开发了PK模型.
- 构建了一个PKPD模型来预测个体ANC,并结合了代谢物数据.
主要成果:
- 整合红细胞代谢物测量改善了模型预测有限的数据.
- 当数据丰富时,模型预测与固定的PK模型相比,可验证现有模型.
- 综合PKPD模型成功地捕获了药物动态.
结论:
- 开发的PKPD模型为了解ALL中的6MP和MTX药理学提供了一个强大的框架.
- 该模型支持通过模拟和优化开发个性化维护治疗策略.
- 这项研究验证了模型结构的适用性,并为未来的ALL治疗研究提供了基础.
更多相关视频
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
相关概念视频
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Physiological Pharmacokinetic Models: Assumption with Protein Binding